GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (STU:I7G) » Definitions » Total Liabilities

Ipsen (STU:I7G) Total Liabilities : €2,499 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Ipsen Total Liabilities?

Ipsen's Total Liabilities for the quarter that ended in Dec. 2023 was €2,499 Mil.

Ipsen's quarterly Total Liabilities increased from Dec. 2022 (€2,271.20 Mil) to Jun. 2023 (€2,687.30 Mil) but then declined from Jun. 2023 (€2,687.30 Mil) to Dec. 2023 (€2,499.10 Mil).

Ipsen's annual Total Liabilities increased from Dec. 2021 (€2,252.80 Mil) to Dec. 2022 (€2,271.20 Mil) and increased from Dec. 2022 (€2,271.20 Mil) to Dec. 2023 (€2,499.10 Mil).


Ipsen Total Liabilities Historical Data

The historical data trend for Ipsen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Total Liabilities Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,553.90 2,179.10 2,252.80 2,271.20 2,499.10

Ipsen Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,252.80 2,441.00 2,271.20 2,687.30 2,499.10

Ipsen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ipsen's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1626.8+(269.7+578.2
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+24.4)
=2,499

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=6322.9-3823.8
=2,499

Ipsen's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1626.8+(269.7+578.2
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+24.4)
=2,499

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=6322.9-3823.8
=2,499

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipsen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ipsen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipsen (STU:I7G) Business Description

Traded in Other Exchanges
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Ipsen (STU:I7G) Headlines

No Headlines